Recent advances in pediatric pharmacokinetics highlight substantial age-dependent physiological changes that require specialised approaches to optimise efficacy and minimise adverse effects in children. This review compares pharmacokinetic differences between adults and children, traditional dosing approaches, and recent developments in Model-Informed Precision Dosing (MIPD), with a focus on Population Pharmacokinetic (PopPK) and Physiologically Based Pharmacokinetic (PBPK) modeling strategies. Recent advances in Bayesian forecasting and the integration of artificial intelligence and machine learning are highlighted for their potential to improve dosing accuracy and clinical decision-making. This article examines current regulatory perspectives on pharmacometric approaches in pediatric medication development and offers insights into evolving standards and guidelines. It also addresses key technical, logistical, and regulatory challenges and potential solutions. Based on these insights, future strategies to improve model-based precision in pediatric dosing are discussed.
Prabakar et al. (2026) studied this question.